Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

Evotec Ag (Adr) ( (EVO) ) has released its Q3 earnings. Here is a breakdown of the information Evotec Ag (Adr) presented to its investors.

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...

Analyst Brendan Smith of TD Cowen maintained a Buy rating on Evotec AG (EVO – Research Report), with a price target of $10.00. Brendan ...

Evotec agreed to sell its chemical API production facility ... Canadian drugmaker Apotex hired banks to prepare for its IPO.

HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (MDAX/TecDAX, ISIN: DE0005664809) (NASDAQ:EVO) today announced its financial results and corporate updates ...

Any significant move would also need support from Evotec’s other major shareholders — Novo Holdings A/S, the parent company of drugmaker Novo Nordisk A/S, as well as Abu Dhabi sovereign fund Mubadala ...